{
    "nctId": "NCT00343668",
    "title": "A Phase II Study of S-1 and Irinotecan Combination Chemotherapy in Patients With Advanced Gastric Cancer as a First-Line Therapy",
    "symPyJSON": {
        "type": "and",
        "operands": [
            {
                "type": "and",
                "operands": [
                    {
                        "type": "variable",
                        "value": "Pathologically proven unresectable adenocarcinoma of stomach"
                    },
                    {
                        "type": "variable",
                        "value": "With uni-dimensionally measurable disease (at least longest diameter 2 cm on conventional CT scan, x-ray or physical examination, or 1 cm on spiral CT scan)"
                    },
                    {
                        "type": "variable",
                        "value": "Age 18 to 70 years old"
                    },
                    {
                        "type": "variable",
                        "value": "Estimated life expectancy of more than 3 months"
                    },
                    {
                        "type": "variable",
                        "value": "ECOG performance status of 2 or lower"
                    },
                    {
                        "type": "variable",
                        "value": "Adequate bone marrow function (absolute neutrophil count [ANC] \u22651,500/\u00b5L, hemoglobin \u22659.0 g/dL, and platelets \u2265100,000/\u00b5L)"
                    },
                    {
                        "type": "variable",
                        "value": "Adequate kidney function (serum creatinine < 1.5 mg/dL)"
                    },
                    {
                        "type": "variable",
                        "value": "Adequate liver function (serum total bilirubin < 2 times the upper normal limit (UNL); serum transaminases levels <3 times [<5 times for patients with liver metastasis] UNL)"
                    },
                    {
                        "type": "variable",
                        "value": "No prior chemotherapy but prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed (but prior adjuvant chemotherapy with capecitabine or S-1 or camptothecin analogues was excluded)"
                    },
                    {
                        "type": "variable",
                        "value": "No prior radiation therapy for at least 4 weeks before enrollment in the study"
                    },
                    {
                        "type": "variable",
                        "value": "Must have minimum age of 18 Years"
                    },
                    {
                        "type": "variable",
                        "value": "Must have maximum age of 70 Years"
                    }
                ]
            },
            {
                "type": "not",
                "operands": [
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Other tumor type than adenocarcinoma"
                            },
                            {
                                "type": "variable",
                                "value": "Central nervous system (CNS) metastases or prior radiation for CNS metastases"
                            },
                            {
                                "type": "variable",
                                "value": "Gastric outlet obstruction or intestinal obstruction"
                            },
                            {
                                "type": "variable",
                                "value": "Evidence of gastrointestinal bleeding"
                            },
                            {
                                "type": "variable",
                                "value": "The patient has bony lesions as the sole evaluable disease"
                            },
                            {
                                "type": "variable",
                                "value": "Past or concurrent history of neoplasm other than stomach cancer, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri"
                            },
                            {
                                "type": "variable",
                                "value": "Pregnant or lactating women, women of childbearing potential not employing adequate contraception"
                            },
                            {
                                "type": "variable",
                                "value": "Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry"
                            },
                            {
                                "type": "variable",
                                "value": "History of significant neurologic or psychiatric disorders including dementia or seizures"
                            },
                            {
                                "type": "variable",
                                "value": "Active uncontrolled infection"
                            },
                            {
                                "type": "variable",
                                "value": "Other serious underlying medical conditions which could impair the ability of the patient to participate in the study"
                            },
                            {
                                "type": "variable",
                                "value": "Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy"
                            },
                            {
                                "type": "variable",
                                "value": "Concomitant drug medication: Warfarin, phenprocoumon (increase bleeding tendency), Increase blood concentration of phenytoin, Sorivudine (inhibit DPD -> increase toxicity according to fluoropyrimidine), Allopurinol (decrease activity of S-1)"
                            }
                        ]
                    }
                ]
            }
        ]
    },
    "symPyExpression": "And(Symbol('Adequate bone marrow function (absolute neutrophil count [ANC] \u22651,500/\u00b5L, hemoglobin \u22659.0 g/dL, and platelets \u2265100,000/\u00b5L)'), Symbol('Adequate kidney function (serum creatinine < 1.5 mg/dL)'), Symbol('Adequate liver function (serum total bilirubin < 2 times the upper normal limit (UNL); serum transaminases levels <3 times [<5 times for patients with liver metastasis] UNL)'), Symbol('Age 18 to 70 years old'), Symbol('ECOG performance status of 2 or lower'), Symbol('Estimated life expectancy of more than 3 months'), Symbol('Must have maximum age of 70 Years'), Symbol('Must have minimum age of 18 Years'), Symbol('No prior chemotherapy but prior adjuvant chemotherapy finished at least 6 months before enrollment was allowed (but prior adjuvant chemotherapy with capecitabine or S-1 or camptothecin analogues was excluded)'), Symbol('No prior radiation therapy for at least 4 weeks before enrollment in the study'), Symbol('Pathologically proven unresectable adenocarcinoma of stomach'), Symbol('With uni-dimensionally measurable disease (at least longest diameter 2 cm on conventional CT scan, x-ray or physical examination, or 1 cm on spiral CT scan)'), Not(Or(Symbol('Active uncontrolled infection'), Symbol('Central nervous system (CNS) metastases or prior radiation for CNS metastases'), Symbol('Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy'), Symbol('Concomitant drug medication: Warfarin, phenprocoumon (increase bleeding tendency), Increase blood concentration of phenytoin, Sorivudine (inhibit DPD -> increase toxicity according to fluoropyrimidine), Allopurinol (decrease activity of S-1)'), Symbol('Evidence of gastrointestinal bleeding'), Symbol('Gastric outlet obstruction or intestinal obstruction'), Symbol('History of significant neurologic or psychiatric disorders including dementia or seizures'), Symbol('Other serious underlying medical conditions which could impair the ability of the patient to participate in the study'), Symbol('Other tumor type than adenocarcinoma'), Symbol('Past or concurrent history of neoplasm other than stomach cancer, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri'), Symbol('Pregnant or lactating women, women of childbearing potential not employing adequate contraception'), Symbol('The patient has bony lesions as the sole evaluable disease'), Symbol('Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry'))))"
}